Frequencies for first 10,000 rows of indi_pt variable in indi2014q1 dataset : 'Preferred Term'-level medical | terminology describing the Indication | for use | Freq. Percent Cum. ----------------------------------------+----------------------------------- 5q minus syndrome | 3 0.03 0.03 Abdominal discomfort | 11 0.11 0.14 Abdominal distension | 2 0.02 0.16 Abdominal pain | 7 0.07 0.23 Abdominal pain upper | 20 0.20 0.43 Abnormal behaviour | 1 0.01 0.44 Abstains from alcohol | 1 0.01 0.45 Accidental exposure to product | 1 0.01 0.46 Acne | 164 1.64 2.10 Acne cystic | 14 0.14 2.24 Acrochordon | 1 0.01 2.25 Acromegaly | 5 0.05 2.30 Acute coronary syndrome | 4 0.04 2.34 Acute graft versus host disease | 2 0.02 2.36 Acute leukaemia | 2 0.02 2.38 Acute lymphocytic leukaemia | 9 0.09 2.47 Acute lymphocytic leukaemia recurrent | 2 0.02 2.49 Acute monocytic leukaemia | 2 0.02 2.51 Acute myeloid leukaemia | 24 0.24 2.75 Acute myelomonocytic leukaemia | 2 0.02 2.77 Acute myocardial infarction | 3 0.03 2.80 Acute sinusitis | 2 0.02 2.82 Adenocarcinoma pancreas | 2 0.02 2.84 Adjustment disorder | 1 0.01 2.85 Adrenal insufficiency | 2 0.02 2.87 Adverse event | 1 0.01 2.88 Affective disorder | 20 0.20 3.08 Age-related macular degeneration | 8 0.08 3.16 Aggression | 4 0.04 3.20 Agitation | 9 0.09 3.29 Agoraphobia | 7 0.07 3.36 Alcoholism | 4 0.04 3.40 Allergic sinusitis | 2 0.02 3.42 Allergy prophylaxis | 1 0.01 3.43 Allogenic bone marrow transplantation.. | 1 0.01 3.44 Alopecia | 2 0.02 3.46 Alport's syndrome | 3 0.03 3.49 Amyloidosis | 9 0.09 3.58 Anaemia | 13 0.13 3.71 Anaemia prophylaxis | 1 0.01 3.72 Anaesthesia | 7 0.07 3.79 Anal fistula | 3 0.03 3.82 Analgesic therapy | 22 0.22 4.04 Androgen deficiency | 2 0.02 4.06 Angina pectoris | 11 0.11 4.17 Angiodysplasia | 1 0.01 4.18 Angiogram | 3 0.03 4.21 Angiopathy | 2 0.02 4.23 Ankylosing spondylitis | 20 0.20 4.43 Anosmia | 2 0.02 4.45 Antacid therapy | 3 0.03 4.48 Antibiotic prophylaxis | 3 0.03 4.51 Antibiotic therapy | 3 0.03 4.54 Anticoagulant therapy | 34 0.34 4.88 Antidepressant therapy | 9 0.09 4.97 Antiemetic supportive care | 2 0.02 4.99 Antifungal prophylaxis | 1 0.01 5.00 Antiinflammatory therapy | 6 0.06 5.06 Antiplatelet therapy | 2 0.02 5.08 Antiretroviral therapy | 8 0.08 5.16 Antiviral treatment | 1 0.01 5.17 Anxiety | 139 1.39 6.56 Anxiety disorder | 3 0.03 6.59 Anxiolytic therapy | 1 0.01 6.60 Aortic valve disease | 1 0.01 6.61 Aplastic anaemia | 2 0.02 6.63 Arrhythmia | 5 0.05 6.68 Arterial disorder | 3 0.03 6.71 Arterial occlusive disease | 2 0.02 6.73 Arteriosclerosis | 1 0.01 6.74 Arteriosclerosis coronary artery | 1 0.01 6.75 Arthralgia | 37 0.37 7.12 Arthritis | 35 0.35 7.47 Arthritis reactive | 1 0.01 7.48 Arthrogram | 1 0.01 7.49 Arthropathy | 4 0.04 7.53 Artificial menopause | 1 0.01 7.54 Ascites | 2 0.02 7.56 Asthenia | 3 0.03 7.59 Asthma | 138 1.38 8.97 Atrial fibrillation | 59 0.59 9.56 Atrioventricular block | 1 0.01 9.57 Attention deficit/hyperactivity disor.. | 21 0.21 9.78 Autoimmune disorder | 1 0.01 9.79 Autoimmune thyroiditis | 2 0.02 9.81 Autonomic neuropathy | 1 0.01 9.82 B-cell lymphoma | 1 0.01 9.83 Back disorder | 1 0.01 9.84 Back injury | 2 0.02 9.86 Back pain | 188 1.88 11.74 Barrett's oesophagus | 8 0.08 11.82 Basal cell carcinoma | 4 0.04 11.86 Behcet's syndrome | 5 0.05 11.91 Benign intracranial hypertension | 2 0.02 11.93 Benign prostatic hyperplasia | 7 0.07 12.00 Binge eating | 1 0.01 12.01 Bipolar I disorder | 17 0.17 12.18 Bipolar disorder | 85 0.85 13.03 Bladder disorder | 7 0.07 13.10 Bladder spasm | 1 0.01 13.11 Blepharospasm | 1 0.01 13.12 Blood cholesterol | 23 0.23 13.35 Blood cholesterol abnormal | 35 0.35 13.70 Blood cholesterol decreased | 2 0.02 13.72 Blood cholesterol increased | 50 0.50 14.22 Blood disorder | 2 0.02 14.24 Blood glucose | 1 0.01 14.25 Blood glucose abnormal | 1 0.01 14.26 Blood glucose increased | 2 0.02 14.28 Blood insulin abnormal | 1 0.01 14.29 Blood potassium decreased | 5 0.05 14.34 Blood pressure | 38 0.38 14.72 Blood pressure abnormal | 61 0.61 15.33 Blood pressure diastolic increased | 1 0.01 15.34 Blood pressure increased | 2 0.02 15.36 Blood sodium decreased | 1 0.01 15.37 Blood testosterone decreased | 1 0.01 15.38 Blood triglycerides | 5 0.05 15.43 Blood triglycerides increased | 1 0.01 15.44 Body temperature increased | 5 0.05 15.49 Bone disorder | 15 0.15 15.64 Bone marrow transplant | 4 0.04 15.68 Bone pain | 2 0.02 15.70 Borrelia infection | 1 0.01 15.71 Bowel preparation | 1 0.01 15.72 Brain neoplasm | 2 0.02 15.74 Breakthrough pain | 37 0.37 16.11 Breast cancer | 48 0.48 16.59 Breast cancer female | 1 0.01 16.60 Breast cancer metastatic | 21 0.21 16.81 Breast cancer recurrent | 2 0.02 16.83 Bronchial carcinoma | 1 0.01 16.84 Bronchiolitis | 6 0.06 16.90 Bronchioloalveolar carcinoma | 1 0.01 16.91 Bronchitis | 5 0.05 16.96 Bronchitis chronic | 2 0.02 16.98 Bronchopulmonary aspergillosis | 3 0.03 17.01 Burkitt's lymphoma | 2 0.02 17.03 Burning sensation | 4 0.04 17.07 Cancer pain | 11 0.11 17.18 Carcinoid tumour | 1 0.01 17.19 Cardiac assistance device user | 2 0.02 17.21 Cardiac disorder | 47 0.47 17.68 Cardiac failure | 15 0.15 17.83 Cardiac failure chronic | 19 0.19 18.02 Cardiac failure congestive | 8 0.08 18.10 Cardiac fibrillation | 1 0.01 18.11 Cardiac murmur | 2 0.02 18.13 Cardiovascular disorder | 11 0.11 18.24 Cardiovascular event prophylaxis | 10 0.10 18.34 Cardiovascular insufficiency | 1 0.01 18.35 Cartilage atrophy | 1 0.01 18.36 Castleman's disease | 14 0.14 18.50 Cataplexy | 4 0.04 18.54 Catatonia | 1 0.01 18.55 Catheter management | 1 0.01 18.56 Cerebral infarction | 1 0.01 18.57 Cerebral vasoconstriction | 2 0.02 18.59 Cerebrovascular accident | 6 0.06 18.65 Cerebrovascular accident prophylaxis | 3 0.03 18.68 Cervical spinal stenosis | 1 0.01 18.69 Chemotherapy | 3 0.03 18.72 Chest discomfort | 2 0.02 18.74 Chest pain | 24 0.24 18.98 Chills | 1 0.01 18.99 Choking | 1 0.01 19.00 Cholecystectomy | 1 0.01 19.01 Cholelithiasis | 1 0.01 19.02 Chondrosarcoma | 1 0.01 19.03 Chromosome analysis abnormal | 1 0.01 19.04 Chronic hepatitis B | 4 0.04 19.08 Chronic hepatitis C | 21 0.21 19.29 Chronic lymphocytic leukaemia | 14 0.14 19.43 Chronic myeloid leukaemia | 20 0.20 19.63 Chronic myelomonocytic leukaemia | 2 0.02 19.65 Chronic obstructive pulmonary disease | 54 0.54 20.19 Chronic sinusitis | 2 0.02 20.21 Clear cell renal cell carcinoma | 3 0.03 20.24 Clonic convulsion | 3 0.03 20.27 Coeliac disease | 1 0.01 20.28 Colitis | 10 0.10 20.38 Colitis ulcerative | 39 0.39 20.77 Colon cancer | 5 0.05 20.82 Colon cancer stage III | 2 0.02 20.84 Colon injury | 1 0.01 20.85 Colonoscopy | 84 0.84 21.69 Colony stimulating factor prophylaxis | 1 0.01 21.70 Colorectal cancer | 5 0.05 21.75 Colorectal cancer metastatic | 12 0.12 21.87 Complex regional pain syndrome | 2 0.02 21.89 Computerised tomogram | 1 0.01 21.90 Computerised tomogram abdomen | 2 0.02 21.92 Congenital aplastic anaemia | 1 0.01 21.93 Congenital cystic kidney disease | 1 0.01 21.94 Constipation | 30 0.30 22.24 Constipation prophylaxis | 2 0.02 22.26 Contraception | 223 2.23 24.49 Contusion | 1 0.01 24.50 Conversion disorder | 4 0.04 24.54 Convulsion | 32 0.32 24.86 Convulsion prophylaxis | 4 0.04 24.90 Coronary artery disease | 14 0.14 25.04 Cough | 6 0.06 25.10 Crohn's disease | 98 0.98 26.08 Cryopyrin associated periodic syndrome | 1 0.01 26.09 Cutaneous lupus erythematosus | 1 0.01 26.10 Cyst | 2 0.02 26.12 Cystic fibrosis | 1 0.01 26.13 Cystitis | 3 0.03 26.16 Cystoid macular oedema | 1 0.01 26.17 Cytomegalovirus infection | 3 0.03 26.20 Death of relative | 2 0.02 26.22 Decreased appetite | 3 0.03 26.25 Deep vein thrombosis | 8 0.08 26.33 Delusional disorder, unspecified type | 1 0.01 26.34 Dementia | 6 0.06 26.40 Dementia Alzheimer's type | 8 0.08 26.48 Dental disorder prophylaxis | 1 0.01 26.49 Depressed level of consciousness | 1 0.01 26.50 Depression | 207 2.07 28.57 Depressive symptom | 1 0.01 28.58 Dermatitis | 2 0.02 28.60 Dermatitis allergic | 1 0.01 28.61 Dermatitis atopic | 1 0.01 28.62 Dermatitis contact | 1 0.01 28.63 Developmental delay | 2 0.02 28.65 Device therapy | 1 0.01 28.66 Diabetes insipidus | 2 0.02 28.68 Diabetes mellitus | 282 2.82 31.50 Diabetes mellitus management | 1 0.01 31.51 Diabetic neuropathy | 6 0.06 31.57 Diabetic retinal oedema | 1 0.01 31.58 Diabetic retinopathy | 1 0.01 31.59 Diarrhoea | 16 0.16 31.75 Diastolic dysfunction | 3 0.03 31.78 Diffuse large B-cell lymphoma | 7 0.07 31.85 Diffuse large B-cell lymphoma recurrent | 4 0.04 31.89 Diuretic therapy | 15 0.15 32.04 Diverticulitis | 2 0.02 32.06 Drug abuse | 2 0.02 32.08 Drug dependence | 55 0.55 32.63 Drug toxicity prophylaxis | 1 0.01 32.64 Drug withdrawal syndrome | 1 0.01 32.65 Dry eye | 6 0.06 32.71 Dry skin | 2 0.02 32.73 Duchenne muscular dystrophy | 1 0.01 32.74 Duodenal ulcer | 1 0.01 32.75 Duodenal ulcer haemorrhage | 3 0.03 32.78 Dysfunctional uterine bleeding | 1 0.01 32.79 Dyslipidaemia | 5 0.05 32.84 Dysmenorrhoea | 14 0.14 32.98 Dyspepsia | 50 0.50 33.48 Dysphagia | 3 0.03 33.51 Dysphoria | 1 0.01 33.52 Dyspnoea | 21 0.21 33.73 Dystonia | 3 0.03 33.76 Dysuria | 3 0.03 33.79 Ear infection | 2 0.02 33.81 Ear pain | 1 0.01 33.82 Eating disorder | 2 0.02 33.84 Eczema | 2 0.02 33.86 Electrolyte imbalance | 1 0.01 33.87 Electrolyte substitution therapy | 2 0.02 33.89 Emotional distress | 1 0.01 33.90 Emphysema | 7 0.07 33.97 Encephalopathy | 1 0.01 33.98 Endometriosis | 2 0.02 34.00 Enuresis | 3 0.03 34.03 Epidural analgesia | 2 0.02 34.05 Epigastric discomfort | 1 0.01 34.06 Epilepsy | 35 0.35 34.41 Epistaxis | 1 0.01 34.42 Erosive oesophagitis | 8 0.08 34.50 Erysipelas | 1 0.01 34.51 Essential hypertension | 3 0.03 34.54 Eustachian tube disorder | 1 0.01 34.55 Exposure during breast feeding | 1 0.01 34.56 Exposure during pregnancy | 1 0.01 34.57 Exposure via body fluid | 1 0.01 34.58 Extragonadal primary germ cell tumour.. | 2 0.02 34.60 Extranodal marginal zone B-cell lymph.. | 1 0.01 34.61 Extrapyramidal disorder | 5 0.05 34.66 Eye pain | 1 0.01 34.67 Fabry's disease | 1 0.01 34.68 Facial pain | 1 0.01 34.69 Factor VIII deficiency | 1 0.01 34.70 Fatigue | 10 0.10 34.80 Febrile bone marrow aplasia | 4 0.04 34.84 Febrile neutropenia | 7 0.07 34.91 Feeling cold | 2 0.02 34.93 Feeling of relaxation | 1 0.01 34.94 Femoral neck fracture | 1 0.01 34.95 Fibroma | 1 0.01 34.96 Fibromyalgia | 36 0.36 35.32 Fistulogram | 4 0.04 35.36 Flank pain | 2 0.02 35.38 Flatulence | 1 0.01 35.39 Fluid retention | 9 0.09 35.48 Focal segmental glomerulosclerosis | 4 0.04 35.52 Foetal exposure during pregnancy | 55 0.55 36.07 Folate deficiency | 1 0.01 36.08 Folliculitis | 1 0.01 36.09 Foot fracture | 3 0.03 36.12 Fracture | 1 0.01 36.13 Fracture pain | 1 0.01 36.14 Fungal infection | 2 0.02 36.16 Fungal skin infection | 1 0.01 36.17 Gait disturbance | 1 0.01 36.18 Gallbladder disorder | 1 0.01 36.19 Gastric bypass | 4 0.04 36.23 Gastric cancer | 11 0.11 36.34 Gastric disorder | 17 0.17 36.51 Gastric pH decreased | 1 0.01 36.52 Gastric ulcer | 15 0.15 36.67 Gastritis | 21 0.21 36.88 Gastritis prophylaxis | 3 0.03 36.91 Gastroduodenal ulcer | 2 0.02 36.93 Gastroenteritis | 3 0.03 36.96 Gastrointestinal disorder | 3 0.03 36.99 Gastrointestinal disorder therapy | 4 0.04 37.03 Gastrointestinal obstruction | 2 0.02 37.05 Gastrointestinal pain | 4 0.04 37.09 Gastrointestinal stromal tumour | 1 0.01 37.10 Gastrooesophageal cancer | 8 0.08 37.18 Gastrooesophageal reflux disease | 311 3.11 40.29 General anaesthesia | 9 0.09 40.38 General physical condition | 3 0.03 40.41 General symptom | 1 0.01 40.42 Generalised anxiety disorder | 2 0.02 40.44 Glaucoma | 4 0.04 40.48 Glioblastoma | 10 0.10 40.58 Glioblastoma multiforme | 4 0.04 40.62 Glioma | 2 0.02 40.64 Glucose tolerance impaired | 2 0.02 40.66 Goitre | 2 0.02 40.68 Gout | 5 0.05 40.73 Grand mal convulsion | 2 0.02 40.75 Granulomatosis with polyangiitis | 2 0.02 40.77 Growth hormone deficiency | 3 0.03 40.80 Growth retardation | 1 0.01 40.81 Gun shot wound | 4 0.04 40.85 HER-2 positive breast cancer | 6 0.06 40.91 HIV infection | 58 0.58 41.49 Haematochezia | 1 0.01 41.50 Haemoglobin decreased | 2 0.02 41.52 Haemolysis | 2 0.02 41.54 Haemolytic uraemic syndrome | 7 0.07 41.61 Haemosiderosis | 1 0.01 41.62 Hair disorder | 1 0.01 41.63 Hairy cell leukaemia | 1 0.01 41.64 Hallucination | 2 0.02 41.66 Head and neck cancer | 3 0.03 41.69 Headache | 39 0.39 42.08 Heart disease congenital | 1 0.01 42.09 Heart rate | 1 0.01 42.10 Heart rate abnormal | 1 0.01 42.11 Heart rate irregular | 1 0.01 42.12 Heart transplant | 1 0.01 42.13 Heart valve stenosis | 1 0.01 42.14 Helicobacter gastritis | 1 0.01 42.15 Helicobacter infection | 2 0.02 42.17 Hemiparesis | 1 0.01 42.18 Hepatic cirrhosis | 1 0.01 42.19 Hepatic function abnormal | 1 0.01 42.20 Hepatitis B | 2 0.02 42.22 Hepatitis C | 10 0.10 42.32 Hepatocellular carcinoma | 21 0.21 42.53 Herpes simplex | 1 0.01 42.54 Herpes virus infection | 4 0.04 42.58 Herpes zoster | 3 0.03 42.61 Hiatus hernia | 24 0.24 42.85 Hip arthroplasty | 1 0.01 42.86 Histiocytosis haematophagic | 1 0.01 42.87 Hormone level abnormal | 2 0.02 42.89 Hormone replacement therapy | 16 0.16 43.05 Hormone therapy | 4 0.04 43.09 Hot flush | 3 0.03 43.12 Hypercalcaemia | 1 0.01 43.13 Hyperchlorhydria | 3 0.03 43.16 Hypercholesterolaemia | 21 0.21 43.37 Hyperglycaemia | 5 0.05 43.42 Hyperhidrosis | 2 0.02 43.44 Hyperlipidaemia | 23 0.23 43.67 Hyperparathyroidism secondary | 6 0.06 43.73 Hyperphosphataemia | 9 0.09 43.82 Hypersensitivity | 28 0.28 44.10 Hypersomnia | 5 0.05 44.15 Hypertension | 267 2.67 46.82 Hypertensive heart disease | 8 0.08 46.90 Hyperthyroidism | 3 0.03 46.93 Hypertonic bladder | 1 0.01 46.94 Hypertriglyceridaemia | 3 0.03 46.97 Hyperuricaemia | 9 0.09 47.06 Hypoaesthesia | 4 0.04 47.10 Hypocalcaemia | 2 0.02 47.12 Hypocholesterolaemia | 1 0.01 47.13 Hypokalaemia | 3 0.03 47.16 Hyponatraemia | 1 0.01 47.17 Hypopituitarism | 2 0.02 47.19 Hypothyroidism | 45 0.45 47.64 Hypotrichosis | 1 0.01 47.65 Hypovitaminosis | 1 0.01 47.66 Hysterectomy | 2 0.02 47.68 Ichthyosis | 1 0.01 47.69 Ill-defined disorder | 11 0.11 47.80 Immune system disorder | 3 0.03 47.83 Immune thrombocytopenic purpura | 14 0.14 47.97 Immunisation | 2 0.02 47.99 Immunosuppressant drug therapy | 2 0.02 48.01 Immunosuppression | 7 0.07 48.08 Impaired gastric emptying | 1 0.01 48.09 Inappropriate affect | 4 0.04 48.13 Increased bronchial secretion | 1 0.01 48.14 Infection | 9 0.09 48.23 Infection prophylaxis | 8 0.08 48.31 Inflammation | 4 0.04 48.35 Inflammatory bowel disease | 4 0.04 48.39 Influenza | 2 0.02 48.41 Influenza like illness | 1 0.01 48.42 Inhalation therapy | 2 0.02 48.44 Injury | 4 0.04 48.48 Insomnia | 67 0.67 49.15 Interstitial lung disease | 1 0.01 49.16 Intervertebral disc degeneration | 15 0.15 49.31 Intervertebral disc disorder | 1 0.01 49.32 Intervertebral disc protrusion | 5 0.05 49.37 Intestinal ischaemia | 1 0.01 49.38 Intracranial pressure increased | 1 0.01 49.39 Intraocular pressure increased | 1 0.01 49.40 Iron deficiency | 1 0.01 49.41 Iron deficiency anaemia | 2 0.02 49.43 Iron overload | 9 0.09 49.52 Irregular sleep phase | 1 0.01 49.53 Irritable bowel syndrome | 2 0.02 49.55 Ischaemia | 1 0.01 49.56 Joint injury | 1 0.01 49.57 Juvenile idiopathic arthritis | 6 0.06 49.63 Kidney infection | 1 0.01 49.64 Knee operation | 1 0.01 49.65 Lacrimation increased | 1 0.01 49.66 Lacunar infarction | 1 0.01 49.67 Large cell lung cancer | 1 0.01 49.68 Leukopenia | 1 0.01 49.69 Limb discomfort | 1 0.01 49.70 Limb injury | 1 0.01 49.71 Lipids increased | 1 0.01 49.72 Liver disorder | 2 0.02 49.74 Liver transplant | 5 0.05 49.79 Liver transplant rejection | 4 0.04 49.83 Local swelling | 4 0.04 49.87 Loss of consciousness | 2 0.02 49.89 Low density lipoprotein increased | 1 0.01 49.90 Lower limb fracture | 1 0.01 49.91 Lower respiratory tract infection | 1 0.01 49.92 Lumbar radiculopathy | 1 0.01 49.93 Lung adenocarcinoma | 3 0.03 49.96 Lung adenocarcinoma stage IV | 3 0.03 49.99 Lung disorder | 2 0.02 50.01 Lung neoplasm malignant | 6 0.06 50.07 Lupus nephritis | 2 0.02 50.09 Lymphoedema | 3 0.03 50.12 Lymphoma | 22 0.22 50.34 Macular degeneration | 2 0.02 50.36 Maculopathy | 1 0.01 50.37 Major depression | 14 0.14 50.51 Malaria prophylaxis | 2 0.02 50.53 Malignant histiocytosis | 5 0.05 50.58 Malignant lymphoid neoplasm | 6 0.06 50.64 Malignant melanoma | 10 0.10 50.74 Malignant neoplasm of pleura | 1 0.01 50.75 Mania | 2 0.02 50.77 Mantle cell lymphoma | 12 0.12 50.89 Maternal exposure timing unspecified | 4 0.04 50.93 Medical diet | 1 0.01 50.94 Meigs' syndrome | 1 0.01 50.95 Meniere's disease | 1 0.01 50.96 Meningitis | 2 0.02 50.98 Meningitis viral | 1 0.01 50.99 Menopausal symptoms | 3 0.03 51.02 Menopause | 9 0.09 51.11 Menorrhagia | 21 0.21 51.32 Menstrual cycle management | 14 0.14 51.46 Menstrual discomfort | 2 0.02 51.48 Menstrual disorder | 4 0.04 51.52 Menstruation irregular | 14 0.14 51.66 Mental disorder | 10 0.10 51.76 Metastases to bone | 4 0.04 51.80 Metastases to breast | 2 0.02 51.82 Metastases to central nervous system | 1 0.01 51.83 Metastases to liver | 1 0.01 51.84 Metastases to lymph nodes | 2 0.02 51.86 Metastasis | 1 0.01 51.87 Metastatic gastric cancer | 4 0.04 51.91 Metastatic malignant melanoma | 4 0.04 51.95 Metastatic pain | 1 0.01 51.96 Metastatic renal cell carcinoma | 7 0.07 52.03 Metrorrhagia | 1 0.01 52.04 Micturition disorder | 1 0.01 52.05 Micturition urgency | 2 0.02 52.07 Migraine | 59 0.59 52.66 Migraine prophylaxis | 2 0.02 52.68 Migraine with aura | 1 0.01 52.69 Mineral supplementation | 8 0.08 52.77 Mitral valve replacement | 2 0.02 52.79 Mood altered | 5 0.05 52.84 Mood swings | 7 0.07 52.91 Motion sickness | 1 0.01 52.92 Muckle-Wells syndrome | 1 0.01 52.93 Mucopolysaccharidosis II | 2 0.02 52.95 Mucosal inflammation | 1 0.01 52.96 Multiple allergies | 39 0.39 53.35 Multiple sclerosis | 441 4.41 57.76 Multiple sclerosis relapse | 1 0.01 57.77 Muscle disorder | 2 0.02 57.79 Muscle relaxant therapy | 15 0.15 57.94 Muscle spasms | 45 0.45 58.39 Muscle spasticity | 6 0.06 58.45 Muscular weakness | 1 0.01 58.46 Musculoskeletal pain | 7 0.07 58.53 Myalgia | 10 0.10 58.63 Myasthenia gravis | 1 0.01 58.64 Myelodysplastic syndrome | 16 0.16 58.80 Myelodysplastic syndrome transformation | 1 0.01 58.81 Myocardial infarction | 4 0.04 58.85 Myocardial ischaemia | 8 0.08 58.93 Nail bed disorder | 1 0.01 58.94 Nail disorder | 3 0.03 58.97 Narcolepsy | 4 0.04 59.01 Nasal congestion | 2 0.02 59.03 Nasal decongestion therapy | 1 0.01 59.04 Nasal discomfort | 1 0.01 59.05 Nasopharyngitis | 7 0.07 59.12 Nausea | 40 0.40 59.52 Neck pain | 25 0.25 59.77 Neoplasm malignant | 4 0.04 59.81 Neoplasm prophylaxis | 1 0.01 59.82 Nephrogenic anaemia | 1 0.01 59.83 Nephrolithiasis | 2 0.02 59.85 Nephropathy | 1 0.01 59.86 Nephrotic syndrome | 1 0.01 59.87 Nerve compression | 1 0.01 59.88 Nerve injury | 10 0.10 59.98 Nervous system disorder | 11 0.11 60.09 Nervousness | 8 0.08 60.17 Neuralgia | 20 0.20 60.37 Neuroendocrine carcinoma | 2 0.02 60.39 Neuroendocrine tumour | 2 0.02 60.41 Neurogenic bladder | 1 0.01 60.42 Neuromuscular blockade | 1 0.01 60.43 Neuropathy peripheral | 29 0.29 60.72 Neutropenia | 2 0.02 60.74 Niemann-Pick disease | 1 0.01 60.75 Nocturia | 1 0.01 60.76 Non-Hodgkin's lymphoma | 4 0.04 60.80 Non-small cell lung cancer | 17 0.17 60.97 Non-small cell lung cancer metastatic | 3 0.03 61.00 Non-small cell lung cancer stage III | 1 0.01 61.01 Nuclear magnetic resonance imaging | 14 0.14 61.15 Nuclear magnetic resonance imaging br.. | 2 0.02 61.17 Nutritional supplementation | 16 0.16 61.33 Obsessive-compulsive disorder | 10 0.10 61.43 Ocular hyperaemia | 1 0.01 61.44 Oculogyric crisis | 1 0.01 61.45 Oedema | 11 0.11 61.56 Oedema peripheral | 3 0.03 61.59 Oesophageal adenocarcinoma | 3 0.03 61.62 Oesophageal carcinoma | 1 0.01 61.63 Oesophageal disorder | 1 0.01 61.64 Oesophageal pain | 4 0.04 61.68 Oesophageal ulcer | 2 0.02 61.70 Oesophagitis | 1 0.01 61.71 Oesophagogastroduodenoscopy | 1 0.01 61.72 Oestrogen replacement therapy | 2 0.02 61.74 Off label use | 4 0.04 61.78 Oral candidiasis | 1 0.01 61.79 Oral contraception | 36 0.36 62.15 Oral herpes | 2 0.02 62.17 Oral infection | 2 0.02 62.19 Oropharyngeal pain | 3 0.03 62.22 Osteoarthritis | 14 0.14 62.36 Osteomyelitis chronic | 8 0.08 62.44 Osteonecrosis | 3 0.03 62.47 Osteopenia | 20 0.20 62.67 Osteoporosis | 74 0.74 63.41 Osteoporosis postmenopausal | 3 0.03 63.44 Osteoporosis prophylaxis | 10 0.10 63.54 Osteoporotic fracture | 1 0.01 63.55 Otitis media | 1 0.01 63.56 Ovarian cyst | 8 0.08 63.64 Ovarian failure | 1 0.01 63.65 Pain | 411 4.11 67.76 Pain in extremity | 15 0.15 67.91 Pain management | 18 0.18 68.09 Pain of skin | 3 0.03 68.12 Pain prophylaxis | 1 0.01 68.13 Palliative care | 2 0.02 68.15 Palpitations | 4 0.04 68.19 Pancreatic carcinoma | 3 0.03 68.22 Pancreatic carcinoma metastatic | 1 0.01 68.23 Pancreatic disorder | 2 0.02 68.25 Pancreatic neuroendocrine tumour | 5 0.05 68.30 Pancreatitis | 5 0.05 68.35 Pancreatitis chronic | 1 0.01 68.36 Pancytopenia | 2 0.02 68.38 Panic attack | 22 0.22 68.60 Paraesthesia | 2 0.02 68.62 Parkinson's disease | 39 0.39 69.01 Paroxysmal nocturnal haemoglobinuria | 113 1.13 70.14 Pathological fracture | 4 0.04 70.18 Pemphigus | 3 0.03 70.21 Peptic ulcer | 5 0.05 70.26 Pericardial effusion | 3 0.03 70.29 Peripheral arterial occlusive disease | 3 0.03 70.32 Peripheral ischaemia | 2 0.02 70.34 Peripheral vascular disorder | 1 0.01 70.35 Peritoneal dialysis | 8 0.08 70.43 Petit mal epilepsy | 1 0.01 70.44 Pharyngitis | 1 0.01 70.45 Pharyngitis streptococcal | 1 0.01 70.46 Phlebitis | 1 0.01 70.47 Photopsia | 2 0.02 70.49 Pituitary enlargement | 2 0.02 70.51 Pituitary tumour benign | 4 0.04 70.55 Plasma cell myeloma | 106 1.06 71.61 Plasmacytoma | 2 0.02 71.63 Platelet aggregation | 1 0.01 71.64 Platelet disorder | 2 0.02 71.66 Platelet transfusion | 1 0.01 71.67 Pleural effusion | 1 0.01 71.68 Pneumocystis jirovecii pneumonia | 3 0.03 71.71 Pneumonia | 9 0.09 71.80 Pneumonia bacterial | 1 0.01 71.81 Pollakiuria | 4 0.04 71.85 Polyarthritis | 4 0.04 71.89 Polychondritis | 9 0.09 71.98 Polycystic ovaries | 16 0.16 72.14 Polysubstance dependence | 1 0.01 72.15 Polyuria | 2 0.02 72.17 Poor quality sleep | 2 0.02 72.19 Porphyria acute | 2 0.02 72.21 Post herpetic neuralgia | 1 0.01 72.22 Post procedural complication | 1 0.01 72.23 Post-traumatic epilepsy | 1 0.01 72.24 Post-traumatic neck syndrome | 1 0.01 72.25 Post-traumatic pain | 3 0.03 72.28 Post-traumatic stress disorder | 16 0.16 72.44 Postoperative care | 1 0.01 72.45 Postpartum depression | 1 0.01 72.46 Prader-Willi syndrome | 1 0.01 72.47 Pregnancy | 13 0.13 72.60 Premedication | 51 0.51 73.11 Premenstrual dysphoric disorder | 27 0.27 73.38 Premenstrual syndrome | 91 0.91 74.29 Primary progressive multiple sclerosis | 5 0.05 74.34 Procedural haemorrhage | 5 0.05 74.39 Procedural pain | 4 0.04 74.43 Product used for unknown indication | 1,132 11.32 85.75 Progressive multiple sclerosis | 1 0.01 85.76 Prophylaxis | 163 1.63 87.39 Prophylaxis against gastrointestinal .. | 6 0.06 87.45 Prophylaxis against graft versus host.. | 6 0.06 87.51 Prophylaxis against transplant reject.. | 14 0.14 87.65 Prophylaxis of nausea and vomiting | 3 0.03 87.68 Prostate cancer | 4 0.04 87.72 Prostate cancer metastatic | 10 0.10 87.82 Prostatic disorder | 4 0.04 87.86 Pruritus | 6 0.06 87.92 Psoriasis | 81 0.81 88.73 Psoriatic arthropathy | 22 0.22 88.95 Psychiatric symptom | 1 0.01 88.96 Psychomotor hyperactivity | 1 0.01 88.97 Psychotherapy | 2 0.02 88.99 Psychotic disorder | 14 0.14 89.13 Pulmonary arterial hypertension | 28 0.28 89.41 Pulmonary embolism | 4 0.04 89.45 Pulmonary hypertension | 10 0.10 89.55 Pulmonary oedema | 1 0.01 89.56 Pulmonary tuberculosis | 10 0.10 89.66 Purging | 1 0.01 89.67 Pyrexia | 5 0.05 89.72 Radiculopathy | 1 0.01 89.73 Rash | 4 0.04 89.77 Raynaud's phenomenon | 1 0.01 89.78 Rectal adenocarcinoma | 3 0.03 89.81 Relapsing-remitting multiple sclerosis | 26 0.26 90.07 Renal artery stenosis | 1 0.01 90.08 Renal cancer | 2 0.02 90.10 Renal cancer metastatic | 1 0.01 90.11 Renal cell carcinoma | 7 0.07 90.18 Renal disorder | 7 0.07 90.25 Renal failure | 2 0.02 90.27 Renal failure chronic | 11 0.11 90.38 Renal transplant | 51 0.51 90.89 Respiratory disorder | 3 0.03 90.92 Respiratory failure | 1 0.01 90.93 Respiratory tract infection | 1 0.01 90.94 Restless legs syndrome | 11 0.11 91.05 Restlessness | 1 0.01 91.06 Retinal vein occlusion | 1 0.01 91.07 Rheumatoid arthritis | 201 2.01 93.08 Rhinitis | 1 0.01 93.09 Rhinitis allergic | 5 0.05 93.14 Rhinorrhoea | 1 0.01 93.15 Road traffic accident | 1 0.01 93.16 Rotator cuff syndrome | 1 0.01 93.17 Routine health maintenance | 3 0.03 93.20 Salivary gland cancer | 1 0.01 93.21 Scan with contrast | 4 0.04 93.25 Schizoaffective disorder | 3 0.03 93.28 Schizoaffective disorder bipolar type | 3 0.03 93.31 Schizophrenia | 25 0.25 93.56 Schizophrenia, disorganised type | 5 0.05 93.61 Schizophrenia, paranoid type | 8 0.08 93.69 Schizophrenia, undifferentiated type | 3 0.03 93.72 Sciatica | 2 0.02 93.74 Scleroderma | 2 0.02 93.76 Scoliosis | 2 0.02 93.78 Seasonal allergy | 10 0.10 93.88 Sedation | 11 0.11 93.99 Self-medication | 1 0.01 94.00 Sensation of pressure | 1 0.01 94.01 Sensory disturbance | 1 0.01 94.02 Sepsis | 8 0.08 94.10 Seronegative arthritis | 1 0.01 94.11 Serotonin syndrome | 3 0.03 94.14 Sexual dysfunction | 1 0.01 94.15 Shunt occlusion | 2 0.02 94.17 Sickle cell anaemia | 1 0.01 94.18 Sigmoidoscopy | 2 0.02 94.20 Sinusitis | 7 0.07 94.27 Sjogren's syndrome | 2 0.02 94.29 Skin cancer | 2 0.02 94.31 Skin cancer metastatic | 1 0.01 94.32 Skin lesion | 2 0.02 94.34 Skin papilloma | 1 0.01 94.35 Skin wrinkling | 12 0.12 94.47 Sleep apnoea syndrome | 1 0.01 94.48 Sleep disorder | 89 0.89 95.37 Sleep disorder therapy | 4 0.04 95.41 Small cell lung cancer | 1 0.01 95.42 Smoking cessation therapy | 16 0.16 95.58 Snake bite | 1 0.01 95.59 Social avoidant behaviour | 1 0.01 95.60 Social phobia | 10 0.10 95.70 Somatostatin analogue therapy | 1 0.01 95.71 Somnolence | 1 0.01 95.72 Spastic paralysis | 1 0.01 95.73 Spinal anaesthesia | 2 0.02 95.75 Spinal column stenosis | 1 0.01 95.76 Spinal cord disorder | 1 0.01 95.77 Spinal fracture | 3 0.03 95.80 Spinal myelogram | 1 0.01 95.81 Spinal osteoarthritis | 6 0.06 95.87 Spinal pain | 9 0.09 95.96 Spondyloarthropathy | 2 0.02 95.98 Stem cell transplant | 1 0.01 95.99 Stent placement | 5 0.05 96.04 Stomatitis | 1 0.01 96.05 Stress | 5 0.05 96.10 Stress urinary incontinence | 1 0.01 96.11 Suicide attempt | 2 0.02 96.13 Supplementation therapy | 52 0.52 96.65 Supportive care | 2 0.02 96.67 Surgery | 20 0.20 96.87 Swelling | 3 0.03 96.90 Systemic lupus erythematosus | 3 0.03 96.93 Systemic sclerosis | 1 0.01 96.94 Tachycardia | 2 0.02 96.96 Tachyphrenia | 8 0.08 97.04 Tension headache | 2 0.02 97.06 Terminal state | 1 0.01 97.07 Thalassaemia beta | 1 0.01 97.08 Therapeutic procedure | 1 0.01 97.09 Therapy change | 2 0.02 97.11 Thrombocytopenia | 2 0.02 97.13 Thrombosis | 5 0.05 97.18 Thrombosis in device | 1 0.01 97.19 Thrombosis prophylaxis | 21 0.21 97.40 Thyroid adenoma | 1 0.01 97.41 Thyroid disorder | 39 0.39 97.80 Thyroidectomy | 1 0.01 97.81 Thyroiditis subacute | 1 0.01 97.82 Tinea pedis | 3 0.03 97.85 Tinnitus | 1 0.01 97.86 Tobacco abuse | 1 0.01 97.87 Tobacco user | 3 0.03 97.90 Tooth abscess | 1 0.01 97.91 Transfusion | 2 0.02 97.93 Transplant rejection | 3 0.03 97.96 Tremor | 3 0.03 97.99 Trigeminal neuralgia | 7 0.07 98.06 Tuberous sclerosis | 2 0.02 98.08 Type 1 diabetes mellitus | 7 0.07 98.15 Type 2 diabetes mellitus | 61 0.61 98.76 Type IIa hyperlipidaemia | 1 0.01 98.77 Tyrosinaemia | 1 0.01 98.78 Ulcer | 5 0.05 98.83 Ulcer haemorrhage | 13 0.13 98.96 Unevaluable event | 2 0.02 98.98 Upper respiratory tract infection | 4 0.04 99.02 Upper respiratory tract inflammation | 5 0.05 99.07 Urinary incontinence | 1 0.01 99.08 Urinary tract infection | 14 0.14 99.22 Urosepsis | 4 0.04 99.26 Urticaria | 2 0.02 99.28 Vaginitis bacterial | 1 0.01 99.29 Venogram | 2 0.02 99.31 Venous thrombosis | 2 0.02 99.33 Vertigo | 8 0.08 99.41 Viral infection | 4 0.04 99.45 Vision blurred | 1 0.01 99.46 Vitamin B12 deficiency | 1 0.01 99.47 Vitamin D decreased | 6 0.06 99.53 Vitamin D deficiency | 1 0.01 99.54 Vitamin supplementation | 18 0.18 99.72 Vomiting | 8 0.08 99.80 Vomiting in pregnancy | 1 0.01 99.81 Vulvovaginal candidiasis | 2 0.02 99.83 Waldenstrom's macroglobulinaemia | 5 0.05 99.88 Weight decreased | 3 0.03 99.91 Weight increased | 3 0.03 99.94 Wheezing | 4 0.04 99.98 Zygomycosis | 2 0.02 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 6 Apr 2017